Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to two new employees to purchase an aggregate of 65,000 shares, effective December 1, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to two new employees to purchase an aggregate of 65,000 shares, effective December 1, 2025. The awards were approved by the Compensation Committee under the 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options vest over four years (25% after one year, then monthly over three years), have a 10-year term, and an exercise price of $27.95 per share, equal to the last reported Nasdaq sale price on December 1, 2025. The grants are subject to the Inducement Plan terms.
Details
News Market Reaction – OLMA
On Dec 3, the first trading day after this news, OLMA closed 0.37% above the previous close.
Data tracked by StockTitan Argus for the Dec 3 session.
Key Figures
- Inducement options
- 65,000 shares
- Aggregate stock options granted to two new employees
- Exercise price
- $27.95 per share
- Equal to last reported sale price on December 1, 2025
- Option term
- 10 years
- Contractual term of inducement stock options
- Vesting period
- 4 years
- Options vest over four years subject to continued employment
- Initial vesting
- 25%
- Vests on first anniversary of vesting commencement date
- Remaining vesting schedule
- 36 monthly installments
- Balance vests monthly over following three years
Historical Context
-
Reported 65,000-share employee stock option grants under 2022 Inducement Plan.
-
Planned fireside chat at Evercore Healthcare Conference with webcast access.
-
Closed $218.5M common stock offering including underwriters’ option exercise.
-
Priced 10,000,000-share public offering at $19.00 per share.
-
Announced proposed common stock and pre-funded warrant offering from shelf.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
stock options financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 65,000 shares of the Company's common stock, effective as of December 1, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.